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Pathophysiology of major depressive disorder: mechanisms
involved in etiology are not associated with clinical progression
J Verduijn1, Y Milaneschi1, RA Schoevers2, AM van Hemert3, ATF Beekman1 and BWJH Penninx1
Meta-analyses support the involvement of different pathophysiological mechanisms (inﬂammation, hypothalamic–pituitary
(HPA)-axis, neurotrophic growth and vitamin D) in major depressive disorder (MDD). However, it remains unknown whether
dysregulations in these mechanisms are more pronounced when MDD progresses toward multiple episodes and/or chronicity. We
hypothesized that four central pathophysiological mechanisms of MDD are not only involved in etiology, but also associated with
clinical disease progression. Therefore, we expected to ﬁnd increasingly more dysregulation across consecutive stages of MDD
progression. The sample from the Netherlands Study of Depression and Anxiety (18–65 years) consisted of 230 controls and 2333
participants assigned to a clinical staging model categorizing MDD in eight stages (0, 1A, 1B, 2, 3A, 3B, 3C and 4), from familial risk at
MDD (stage 0) to chronic MDD (stage 4). Analyses of covariance examined whether pathophysiological mechanism markers
(interleukin (IL)-6, C-reactive protein (CRP), cortisol, brain-derived neurotrophic factor and vitamin D) showed a linear trend across
controls, those at risk for MDD (stages 0, 1A and 1B), and those with full-threshold MDD (stages 2, 3A, 3B, 3C and 4). Subsequently,
pathophysiological differences across separate stages within those at risk and with full-threshold MDD were examined. A linear
increase of inﬂammatory markers (CRP P= 0.026; IL-6 P= 0.090), cortisol (P= 0.025) and decrease of vitamin D (Po0.001) was found
across the entire sample (for example, from controls to those at risk and those with full-threshold MDD). Signiﬁcant trends of
dysregulations across stages were present in analyses focusing on at-risk individuals (IL-6 P= 0.050; cortisol P= 0.008; vitamin D
Po0.001); however, no linear trends were found in dysregulations for any of the mechanisms across more progressive stages of
full-threshold MDD. Our results support that the examined pathophysiological mechanisms are involved in MDD’s etiology. These
same mechanisms, however, are less important in clinical progression from ﬁrst to later MDD episodes and toward chronicity.
Translational Psychiatry (2015) 5, e649; doi:10.1038/tp.2015.137; published online 29 September 2015
INTRODUCTION
Several biological mechanisms with a possible role in major
depressive disorder (MDD)’s pathophysiology have been identi-
ﬁed, and it has been hypothesized that these mechanisms may
have a role both in the etiology and progression of the disorder.
Here, we consider four central mechanisms that have substantial
support in literature for their importance in depression etiology
and that have previously been shown to be signiﬁcantly different
in MDD cases and controls in our own sample: inﬂammation,1
hypothalamic–pituitary (HPA) axis,2 neutrophic growth3 and
vitamin D.4 We examined whether progression of MDD at a
clinical level (that is, that what patient/clinicians experience as
more advanced disease stage, which is multiple episodes and/or
chronicity) is paralleled by more pronounced dysregulation in
pathophysiological mechanisms, as evidence for that is scarce.
An upregulation of inﬂammation might be involved in the
development of depression by decreasing the production of
monoamines (for example, serotonin), and increasing the produc-
tion of tryptophan catabolites that are toxic for the brain.5 Meta-
analyses showed that depressed subjects in comparison with
controls had signiﬁcantly increased levels of the pro-inﬂammatory
cytokine interleukin (IL)-6,6–8 and acute phase C-reactive protein
(CRP).6 An example of inﬂammation and MDD progression is the
ﬁnding that tumor necrosis factor alpha was signiﬁcantly higher in
those who experienced 43 episodes.5
Hyperactivity of the HPA-axis as a causal factor in MDD has been
studied extensively.9 This hyperactivity is presumably caused by
malfunctioning of glucocorticoid receptors impairing the negative
feedback circuit of the HPA-axis. Glucocorticoid receptor malfunc-
tion might cause depression via impaired neurogenesis and
reduced hippocampus volumes.10,11 In depressed persons, cortisol
levels might determine risk of12 and time to recurrence13 of an
MDD episode. This suggest that HPA-axis dysfunctioning is
associated with MDD progression.
Low levels of brain-derived neurotrophic factor (BDNF) are seen
as an indicator of reduced neurotropic growth, a third important
possible pathophysiological mechanism of MDD.14 A recent
meta-analysis supports the idea that depressed patients have
lower BDNF levels than controls.15 One study found that drug-free
patients with a long index episode had signiﬁcantly lower BDNF
levels compared with patients with a shorter index episode.16
Recently low levels of vitamin D have been associated with
depression in a meta-analysis.17 Different pathophysiological
mechanisms have been suggested via which vitamin D might
be involved with the etiology or progression of depression.18,19
For instance, vitamin D might be neuroprotective20 by reducing
neurotoxic calcium levels in the brain.21 To our knowledge, no
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studies exist that examined whether vitamin D is associated with
the progression of depression.
The majority of previous studies were based on case–control
comparisons, generally with highly heterogeneous groups with a
different developmental history of depression in terms of severity,
duration or number of experienced disease episodes. Examining
differences in the pathophysiological mechanisms across groups
of patients subdivided according to their developmental depres-
sion trajectory, for instance done by clinical staging, provides the
opportunity to test whether mechanisms that are important for
the etiology of depression are also important in progression of
MDD at a clinical level toward multiple episodes and/or chronicity.
Clinical staging is a tool to describe progression at a clinical level;
it aims to divide the natural course of the disorder in clinically
detectable phases that reﬂect disease progression and that
possess clinical signiﬁcance for prognosis and choice of
treatment.22 Ultimately staging may contribute to early recogni-
tion of MDD development and lead to early intervention that
prevents progression to later stages.23 Staging has proven useful
in the ﬁelds of schizophrenia24,25 and bipolar disorder.26 Currently,
the most used staging model for MDD27 consists of eight stages.
Three at-risk for MDD stages that are concerned with the initial
phases of MDD development and ﬁve full-threshold MDD stages
that reﬂect progression of MDD (Supplement Table 1). The staging
model serves two purposes: (i) it puts the focus on early
recognition of healthy people at risk for depression; (ii) people
with a full-threshold disorder are assigned to consecutive stages
of disease progression based on number and duration of the
current episode, reﬂecting treatment necessity and prognosis.
We examined whether progression of MDD at a clinical level
was paralleled by more pronounced dysregulations in four central
pathophysiological mechanisms. We used staging to deﬁne
clinical progression of MDD. The pathophysiological mechanisms
were studied via markers that reﬂect those mechanisms. In a large
cohort, well characterized in terms of psychiatric diagnoses and
clinical characteristics of MDD, we compared levels of inﬂamma-
tory markers, HPA-axis hormones, BDNF and vitamin D across
healthy controls (HCs), subjects in at-risk for MDD stages and full-
threshold MDD stages. Using this approach, we could test two
assumptions for our study (see Figure 1). First, pathophysiologic
mechanisms are involved in the etiology but are not associated
with clinical progression of MDD. In this case, we expect the
markers to show an increasing gradient of dysregulation across
ascending at-risk stages, which stabilizes across full-threshold
stages. Second, the mechanisms are associated with clinical
progression of MDD as well. If so, we expect the markers to show
continuously increasing dysregulations across consecutive full-
threshold stages. We hypothesized to ﬁnd evidence for the
second assumption, as a few previous studies5 suggest a role of
these mechanisms beyond etiology.
MATERIALS AND METHODS
Sample
Participants were selected from the Netherlands Study of Depression and
Anxiety (NESDA), an on-going cohort study into the etiology and prognosis
of depressive and anxiety disorders. At baseline, 2981 adults (18–65 years)
were selected from community (19%), general practice (54%) and
specialized mental health care (27%) to represent the entire develop-
mental spectrum of both disorders, including HCs. Uniform inclusion and
exclusion criteria were used across recruitment settings and exactly similar
measurement procedures, conducted by the same research staff, were
followed in order to achieve uniform assessments. The methodology of
NESDA has been extensively described elsewhere.28 The ethical review
boards of contributing universities approved the study, and all participants
signed informed consent. At baseline, participants gave blood samples and
underwent a physical examination and a psychiatric interview. The
presence of a depressive (MDD and/or dysthymia) and/or anxiety disorder
(social phobia, agoraphobia, panic- and/or generalized anxiety disorder)
was assessed with the DSM-IV Composite International Diagnostic Inter-
view (CIDI) version 2.1.29 The number of MDD episodes experienced was
extracted from the CIDI. The severity of depression was measured with the
Inventory of Depressive Symptoms (IDS).30 The duration of depressive
symptoms was examined with the Life Chart,31 calculated as the number of
months with depressive symptoms in the 3 years prior to the baseline
interview.
For the current study, we selected 2563 subjects of the baseline sample
who were either HCs or assigned to one of the eight stages of MDD. HCs
(n=230) were without a lifetime diagnosis of MDD or anxiety disorder,
without depressive symptoms (IDS≤ 13) and without a ﬁrst-degree family
member with depression. The assignment of subjects to MDD stages is
described in our previous paper32 and can be found in Supplement Table
1. In short, the assignment to stages is based on the lifetime presence of an
MDD and/or anxiety disorder, the recency of an MDD episode (current if
present in the 6 months prior to baseline, otherwise remitted), severity and
duration of depressive symptoms and the number of episodes. The at-risk
stages consisted of subjects without lifetime MDD or anxiety diagnosis, but
with: stage 0 (n=287) a ﬁrst-degree family member with depression; stage
1A (n=116) mild depressive symptoms; stage 1B (n=834) sub-threshold
depressive symptoms and subjects with remitted MDD. Full-threshold
stages included patients with a current MDD episode: stage 2 (n= 230) ﬁrst
MDD episode; stage 3A (n=129) incomplete remission of ﬁrst episode;
stage 3B (n= 127) recurrence or relapse of MDD; stage 3C (n=394)
multiple relapses; stage 4 (n=216) chronic MDD.
Figure 1. Assumptions of this study. Current studies examined the association between pathophysiological mechanism in a heterogeneous
group of MDD patients (a). We studied the association between pathophysiological mechanisms and groups of MDD patients divided
according to the developmental course of the disorder using staging. We hypothesized that the pathophysiological mechanisms would be
associated with both etiology and clinical progression of MDD. Therefore, we expected increasing dysregulations of the pathophysiological
mechanisms across all the consecutive stages (progression, b). MDD, major depressive disorder.
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Pathophysiological mechanism markers
Inﬂammatory markers. As described in more detail elsewhere,1 CRP and
IL-6 were assayed at the Clinical Chemistry Department of the VU
University Medical Centre from fasting blood samples obtained in the
morning and kept frozen at − 80 ˚C. High-sensitivity plasma levels of CRP
were measured in duplicate by an in-house enzyme-linked immuno-
sorbent assay based on puriﬁed protein and polyclonal anti-CRP antibodies
(Dako, Glostrup, Denmark). Plasma IL-6 levels were measured in duplicate
by a high-sensitivity enzyme-linked immunosorbent assay (PeliKine
Compact ELISA, Sanquin, Amsterdam, The Netherlands). Intra- and inter-
assay coefﬁcients of variation were 5 and 10% for CRP, and 8% and 12% for
IL-6, respectively.
A previous NESDA study1 found that currently depressed men, but not
women, had higher levels of CRP (d=0.21) and IL-6 (d=0.10) than
nondepressed peers. We selected 2526 (98.6%) participants with at least
one available inﬂammatory marker. As the previous NESDA study found
gender-speciﬁc associations between depression and inﬂammatory
markers, we stratiﬁed all inﬂammation analyses by gender.
HPA-axis markers. As described in more detail elsewhere,2 participants
collected saliva samples at home shortly after the baseline interview. Saliva
samples were obtained using Salivettes (Sarstedt, Nümbrecht, Germany) at
seven time points. We used four composite HPA-axis markers (i) the area
under the curve with respect to the ground (AUCg, measure of the total
morning cortisol secretion); and (ii) the area under the curve with respect
to the increase (AUCi, measure of cortisol dynamic) were calculated if all
four morning samples (T1 = awakening time, T2 = 30, T3 = 45, T4 = 60min
later) were available by use of trapezoid formulas;33 (iii) evening cortisol
(the mean of evening levels T5 at 2200 hours and T6 at 2300 hours); and
(iv) the cortisol suppression ratio (a ratio obtained by dividing the cortisol
value at awakening on the ﬁrst day (T1) by the cortisol value at awakening
on the next day (T7) after ingestion of 0.5 mg dexamethasone. This
dexamethasone suppression test examines the functioning of the negative
HPA-axis feedback mechanism. Our analyses included only those
participants (n= 1723, 67.2%) who had information on at least one of
the four HPA-axis markers. Previous NESDA results2 showed that when
compared with HCs, both current and remitted depressed participants had
a (signiﬁcantly) higher AUCg and AUCi, higher evening cortisol levels at
2200 hours, but not a different cortisol suppression ratio.
BDNF. As described in more detail elsewhere,34 serum was separated
immediately after blood draw and stored (at − 85 ˚C) until assay. Serum
BDNF concentrations were determined using the Emax Immuno Assay
system from Promega according to the manufacturer’s protocol (Madison,
WI, USA). Absorbency was read in duplicate using a Bio-Rad Benchmark
microplate reader (Hercules, CA, USA) at 450 nm. The coefﬁcients of variance
ranged between 2.9 and 8.1%. In total, 2498 (97.5%) of the subjects included
in our sample had a BDNF value available. A previous NESDA paper3 showed
that anti-depressant-free currently depressed participants had lower BDNF
levels than both HCs and their medicated currently depressed peers.
Vitamin D. As described in more detail elsewhere,4 vitamin D was
measured by assessing the blood’s circulating levels of 25(OH)D, which is
the combined product of cutaneous synthesis from solar exposure and
dietary sources. Serum 25(OH)D was measured using isotope dilution–
online solid-phase extraction liquid chromatography–tandem mass
spectrometry (ID-XLC-MS/MS).35 Intra- and inter-assay coefﬁcients of
variation were o6% and o8%, respectively, for concentrations between
25 and 180 nmol l− 1. In our sample, 2514 (98.1%) subjects had a vitamin D
value. A previous NESDA study4 showed that compared with controls, both
currently depressed and remitted depressed had lower vitamin D levels.
Covariates
Putative covariates were selected a priori based on previous analyses and
divided into general covariates and covariates speciﬁc per marker. General
covariates included socio-demographic variables age (years), gender
(male/female) and education (years), and health indicators smoking status
(never, former and current), alcohol use (non-drinker o1 units per week;
mild/moderate drinker female 1–14, male 1–21 units per week; heavy
drinker female 414 and male 421 units per week),36 number of self-
reported chronic diseases for which the subject received treatment
(including cardiovascular diseases, diabetes, lung disease, arthritis, cancer,
ulcer, intestinal problem, liver disease, epilepsy and thyroid gland disease),
and body mass index expressed in kg/m2. Participants were asked to bring
their medication packages to the interview after which medications were
registered according to World Health Organization Anatomical Therapeutic
Chemical classiﬁcation.37 Covariates speciﬁc per marker included (1) for
inﬂammation, the use of systemic anti-inﬂammatory drugs (M01A, M01B,
A07EB and A07EC); (2) for the HPA-axis, as reported on the cortisol
sampling form the factors awakening time (hh:mm), work status (yes/no)
and season of saliva collection (light/dark); (3) for BDNF, the use of
systemic anti-inﬂammatory drugs, non-opioid analgesic-antipyretics
(N02BA and N02BE) and selective serotonin reuptake inhibitors (SSRI and
N06AB); (4) for vitamin D, the sampling factor season of blood collection
(light/dark). Season during saliva and blood collection were categorized in
light months (March–September) and dark months (October–February).
Inﬂammation, HPA-axis and vitamin D were not adjusted for antidepres-
sant use, as previous NESDA studies1,2,4 showed that antidepressant use
was not strongly associated with these pathophysiological markers, nor did
they change the association found between depression and markers. In
depressed persons, SSRI users had higher BDNF levels than non-SSRI
users,3 therefore we adjusted our BDNF analyses for SSRI use.
Statistical analyses
Differences in demographic variables and covariates between HCs, the at-
risk for MDD group (stages 0 through 1B) and the full-threshold MDD
group (stages 2 through 4) were examined using analyses of variance and
the χ2-test, followed by Games-Howell post hoc tests.
We compared levels of pathophysiological markers across subjects
assembled using two different strategies (A and B). In strategy A, we
contrasted the three main groups, namely, HCs, at-risk group (stages 0, 1A,
and 1B combined) and full-threshold group (stages 2, 3A, 3B, 3C and 4
combined). In strategy B, we contrasted the separate stages (HCs, 0, 1A, 1B, 2,
3A, 3B, 3C and 4). For both strategy A and B, we conducted two analyses. First
differences in adjusted means of the pathophysiological markers across the
groups/stages were tested with analyses of covariance, followed by Tukey's
Least Signiﬁcant Difference (Tukey's LSD) post hoc pairwise comparisons.
Second, we tested whether the biological measure showed a linear trend
across the groups/stages. For strategy B (separate stages), we performed a
third analysis. To examine whether a trend across all separate stages was
caused by differences within at-risk stages and/or within full-threshold stages,
trend analyses were repeated focusing on either the controls-at-risk stages
(HCs, 0, 1A and 1B) or the full-threshold stages (2, 3A, 3B, 3C and 4).
Finally, we examined whether possible differences in pathophysiological
markers across full-threshold stages could be explained by any of the more
speciﬁc clinical characteristics that were used to create the MDD staging
model: severity (continuous IDS score), duration (% of time with depressive
symptoms in 3 years before baseline) and number of episodes. Analyses
were additionally adjusted for socio-demographic factors (model 1), health
indicators (model 2) and covariates speciﬁc per biological measure (model
3). Pathophysiological markers that were non-normally distributed (inﬂam-
matory markers, mean evening cortisol and cortisol suppression ratio) were
log-transformed before analysis and presented back transformed. All
analyses were performed with SPSS version 20.0. (SPSS, Chicago, IL, USA)
Signiﬁcance was set a Po0.05, using two-tailed tests.
RESULTS
Table 1 shows the socio-demographic and health-related sample
characteristics, and pathophysiological markers across HCs, the at-
risk group and the full-threshold MDD group. As compared with
controls, the at-risk and the full-threshold group were more often
women and current smokers, had lower education, more chronic
diseases and were more likely to use SSRI antidepressants or anti-
inﬂammatory medication. Moreover, the full-threshold and at-risk
groups as compared with HCs had higher CRP and cortisol levels
and lower vitamin D.
Comparing pathophysiological mechanism markers
Between HCs, the at-risk for MDD group and full-threshold MDD
group
Inﬂammatory markers: In men, we found a signiﬁcant linear
trend across the three main groups for both CRP and IL-6 (Table 2),
even after full adjustment. The full-threshold MDD group had
signiﬁcantly higher CRP levels than both HCs and the at-risk
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group, and had signiﬁcantly higher IL-6 levels than HCs. In women,
no such associations were found.
HPA-axis: Both measures of the cortisol awakening response
(AUCg and AUCi) were higher in the at-risk and full-threshold MDD
groups when compared with controls. After full adjustment, AUCg
showed an upward linear trend, but AUCi did not. Mean evening
cortisol and the cortisol suppression ratio did not show a linear
trend across groups after full adjustment.
BDNF: Unadjusted and fully adjusted analyses did not show a
trend of BDNF levels across the three main groups.
Vitamin D: Both unadjusted and adjusted vitamin D levels
showed a highly signiﬁcant linear trend across the three main
groups, with the at-risk group having signiﬁcant lower vitamin D
levels than the HCs and the full-threshold MDD group having
signiﬁcant lower vitamin D levels than the at-risk group.
Between separate stages
Inﬂammatory markers: In both men and women, CRP levels
showed a signiﬁcant linear trend across the separate stages from
controls through stage 4, but no trend existed across the controls/
at-risk stages from controls through stage 1B, or across full-
threshold stages 2 through 4 (Table 3). Furthermore, in both men
and women IL-6 levels showed no signiﬁcant trend across all
stages. However, in women across controls/at-risk stages a
signiﬁcant downward trend was found.
HPA-axis: AUCg showed a signiﬁcant linear trend across the
separate stages, a highly signiﬁcant trend across HCs/at-risk
stages, but no trend across full-threshold stages. AUCi only
showed a linear trend across the HCs/at-risk stages. The lowest
levels of AUCg and AUCi were for stage 1A, those without a history
of MDD but mild symptoms. The highest levels were in stage 3A,
those with an incomplete remission from a ﬁrst episode. After full
adjustment, no linear trend across the stages was found for the
mean evening cortisol or for the cortisol suppression ratio.
BDNF: Unadjusted and fully adjusted analyses did not show any
linear trend for BDNF across stages.
Vitamin D: After full adjustment, vitamin D showed a signiﬁcant
downward linear trend across the separate stages, meaning that





At-risk for MDD group
(stages 0, 1A and 1B)
n=1237
Full-threshold MDD group




Age (years), M (s.d.) 43.5 (13.8) 42.4 (13.5) 40.8 (12.1)hc,ar 0.002
Gender (female), n (%) 132 (57.4) 843 (68.1) 740 (67.5) 0.005
Years of education, M (s.d.) 13.2 (3.1) 12.4 (3.2)hc 11.6 (3.2)hc,ar o0.001
Lifestyle and health factors
BMI (kg/m2), M (s.d.) 25.7 (4.6) 25.4 (4.7) 25.9 (5.4)ar 0.040
Smoking status, n (%) o0.001
Never 92 (40.0) 341 (27.6) 290 (26.5)
Former 88 (38.3) 449 (36.3) 312 (28.5)
Current 50 (21.7) 447 (36.1) 494 (45.1)
Drinking behavior, n (%) o0.001
Non-drinker 54 (23.5) 336 (27.2) 438 (40.0)
Mild-moderate drinker 147 (63.9) 763 (61.7) 531 (48.4)
Heavy drinker 29 (12.6) 138 (11.2) 127 (11.6)
Number of chronic diseases, M (s.d.) 0.45 (0.71) 0.58 (0.85)hc 0.69 (0.95)hc,ar o0.001
Pathophysiological mechanism markers and their speciﬁc covariates P-value
Inﬂammation n= 2526 n= 228 n= 1215 n= 1083
C-reactive protein (mg l− 1)a, M (s.d.) 1.14 (3.09) 1.21 (3.40) 1.39 (3.59)hc,ar 0.010
Interleukin-6 (pgml− 1)a, M (s.d.) 0.71 (2.47) 0.74 (2.57) 0.80 (2.63) 0.100
Systemic anti-inﬂammatory med., n (%) 2 (0.9) 53 (4.4) 50 (4.6) 0.032
HPA-axis function n= 1723 n= 176 n= 871 n= 676
AUCg (nmol l− 1 h− 1), M (s.d.) 18.2 (7.0) 18.9 (6.6) 19.4 (7.4) 0.138
AUCi (nmol l− 1 h− 1), M (s.d.) 0.97 (6.47) 2.39 (6.24)hc 2.41 (6.26)hc 0.022
Mean evening cortisol (nmol l− 1)a, M (s.d.) 4.33 (1.74) 4.65 (1.70) 4.89 (1.74)hc 0.019
Cortisol suppression ratioa, M (s.d.) 2.45 (1.67) 2.38 (1.63) 2.40 (1.68) 0.764
Mean awakening time (h:min), M (s.d.) 7:17 (1:08) 7:27 (1:02) 7:31 (1:10)hc 0.038
Working on day saliva collection, n (%) 122 (69.3) 566 (65.0) 384 (56.8) 0.001
Season saliva collection (light), n (%) 106 (60.2) 547 (62.8) 404 (59.8) 0.453
Neurotrophic growth n= 2498 n= 226 n= 1204 n= 1068
BDNF (ngml− 1), M (s.d.) 9.22 (3.01) 9.01 (3.21) 9.00 (3.41) 0.636
Systemic anti-inﬂammatory med., n (%) 2 (0.9) 53 (4.4) 49 (4.6) 0.034
Non-opioid analgesic-antipyretic med., n (%) 16 (7.1) 112 (9.3) 107 (10.0) 0.383
Anti-depressant: SSRI, n (%) 0 (0.0) 131 (10.9) 319 (29.9) o0.001
Vitamin D n= 2514 n= 228 n= 1212 n= 1074
25(OH)D (nmol l− 1), M (s.d.) 70.7 (27.4) 64.5 (27.7)hc 59.9 (28.5)hc,ar o0.001
Season blood collection (light), n (%) 123 (53.9) 717 (59.2) 593 (55.2) 0.102
Abbreviations: ar, at-risk for MDD group; AUCg/i, area under the curve with respect to the ground/increase; BDNF, brain-derived neurotrophic factor; BMI, body
mass index; hc, healthy controls; HPA, hypothalamic–pituitary axis; M=mean; MDD, major depressive disorder; med., medication; SSRI, selective serotonin
reuptake inhibitors. aLog-transformed factors presented back-transformed. Superscripts (hc,ar) refer to which group this group its outcome differs signﬁcantly
(Po0.05) from; for example, the full-threshold MDD group is signiﬁcantly younger compared with both healthy controls and the at-risk for MDD group.
Differences between groups were examined using Games-Howell post hoc tests.
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later stages had lower vitamin D levels. However, follow-up trend
analyses showed a signiﬁcant downward linear trend across HCs/
at-risk stages, but not across the full-threshold stages.
Full-threshold MDD stages explained by separate clinical character-
istics. As we hardly found any indication that pathophysiological
dysregulation was larger across more progressive MDD stages, we
checked whether indeed associations were also absent for speciﬁc
MDD clinical characteristics. Within full-threshold MDD patients,
only two of the 30 tested associations between characteristics
(severity-, duration- and number of episodes) and the biological
markers were (borderline) signiﬁcant (Table 4). Severity of
depression showed a signiﬁcant negative association with the
AUCg level (β=− 0.086, s.e. = 0.040, P= 0.034), and the number of
Table 2. Adjusted levels of pathophysiological markers across healthy controls, at-risk for MDD group and full-threshold MDD group
n= 2563 Healthy controls
n=230
At-risk for MDD group
(stages 0, 1 A and 1B)
n= 1237
Full-threshold MDD group
(stages 2, 3 A, 3B, 3C and 4)
n= 1096
P for trend
Mean (CI) Mean (CI) Mean (CI)
Inﬂammation n= 228 n= 1215 n= 1083
Male n= 97 n= 389 n= 350
C-reactive protein (mg l− 1)a
Model 1 0.90 (0.71–1.12) 1.04 (0.93–1.17) 1.32 (1.17–1.49)hc,ar o0.001
Model 2 1.01 (0.82–1.24) 1.03 (0.93–1.14) 1.30 (1.16–1.45)hc,ar 0.004
Model 3 1.01 (0.82–1.25) 1.03 (0.93–1.14) 1.29 (1.16–1.44)hc,ar 0.005
Interleukin-6 (pgml− 1)a
Model 1 0.63 (0.53–0.76) 0.81 (0.75–0.89)hc 0.89 (0.81–0.98)hc 0.002
Model 2 0.67 (0.56–0.80) 0.81 (0.74–0.88) 0.88 (0.80–0.97)hc 0.012
Model 3 0.67 (0.56–0.81) 0.81 (0.74–0.88) 0.88 (0.80–0.96)hc 0.013
Female n= 131 n= 826 n= 733
C-reactive protein (mg l− 1)a
Model 1 1.45 (1.17–1.79) 1.35 (1.24–1.47) 1.35 (1.23–1.48) 0.656
Model 2 1.40 (1.15–1.69) 1.42 (1.31–1.53) 1.29 (1.19–1.40) 0.153
Model 3 1.40 (1.15–1.69) 1.42 (1.31–1.53) 1.29 (1.19–1.40) 0.154
Interleukin-6 (pgml− 1)a
Model 1 0.79 (0.67–0.92) 0.72 (0.67–0.76) 0.75 (0.69–0.80) 0.939
Model 2 0.79 (0.67–0.92) 0.74 (0.69–0.78) 0.72 (0.68–0.77) 0.403
Model 3 0.78 (0.67–0.92) 0.74 (0.69–0.79) 0.72 (0.67–0.77) 0.405
HPA-axis n= 176 n= 871 n= 676
AUCg (nmol l− 1 h− 1)
Model 1 18.1 (17.0–19.1) 18.9 (18.4–19.4) 19.4 (18.9–20.0) 0.026
Model 2 18.4 (17.3–19.4) 18.9 (18.4–19.4) 19.4 (18.8–19.9) 0.078
Model 3 18.3 (17.2–19.3) 18.9 (18.4–19.3) 19.4 (18.9–19.9) 0.038
AUCi (nmol l− 1 h− 1)
Model 1 1.13 (0.16–2.09) 2.38 (1.95–2.82) 2.38 (1.88–2.87) 0.106
Model 2 1.30 (0.34–2.27) 2.41 (1.97–2.84) 2.30 (1.80–2.79) 0.255
Model 3 1.21 (0.25–2.16) 2.41 (1.98–2.84) 2.32 (1.82–2.81) 0.190
Mean evening cortisol (nmol l− 1)a
Model 1 4.35 (4.01–4.71) 4.65 (4.48–4.81) 4.90 (4.71–5.11)hc,ar 0.004
Model 2 4.57 (4.24–4.93) 4.66 (4.50–4.82) 4.82 (4.63–5.00) 0.144
Model 3 4.57 (4.24–4.93) 4.66 (4.50–4.82) 4.81 (4.63–5.00) 0.151
Cortisol suppression ratioa
Model 1 2.45 (2.27–2.65) 2.38 (2.29–2.46) 2.40 (2.31–2.50) 0.962
Model 2 2.40 (2.22–2.59) 2.37 (2.29–2.45) 2.43 (2.34–2.53) 0.492
Model 3 2.40 (2.22–2.59) 2.36 (2.28–2.45) 2.43 (2.34–2.53) 0.433
Neurotrophic growth n= 226 n= 1204 n= 1068
BDNF (ngml− 1)
Model 1 9.14 (8.71–9.56) 8.99 (8.81–9.17) 9.04 (8.84–9.24) 0.925
Model 2 9.21 (8.78–9.63) 9.01 (8.83–9.19) 9.00 (8.81–9.20) 0.544
Model 3 9.26 (8.83–9.70) 9.04 (8.85–9.22) 8.96 (8.76–9.16) 0.273
Vitamin D n= 228 n= 1212 n= 1074
25(OH)D (nmol l− 1)
Model 1 71.4 (67.7–75.0) 64.5 (62.9–66.1)hc 59.8 (58.1–61.5)hc,ar o0.001
Model 2 70.5 (66.9–74.1) 63.8 (62.3–65.4)hc 60.7 (59.1–62.4)hc,ar o0.001
Model 3 70.7 (67.1–74.2) 63.7 (62.1–65.2)hc 60.9 (59.3–62.5)hc,ar o0.001
Abbreviations: ar, at-risk for MDD group; AUCg/i, area under the curve with respect to the ground/increase; BDNF, brain-derived neurotrophic factor; CI,
conﬁdence interval; hc, healthy controls; HPA, hypothalamic–pituitary axis; MDD, major depressive disorder. aLog-transformed factors presented back-
transformed. Superscripts (hc,ar) refer to which group this group its outcome differs signiﬁcantly (Po0.05) from; for example, the full-threshold MDD group has
signiﬁcantly lower vitamin D values in model 3 than both healthy controls and the at-risk for MDD group. Differences between groups were examined using
Tukey's LSD post hoc tests. Model 1: adjusted for age; gender (except inﬂammation analyses, as these were stratiﬁed by gender); years of education. Model 2:
additionally adjusted for alcohol status; smoking status; number of chronic diseases under treatment; body mass index. Model 3: additionally adjusted for
covariates speciﬁc for the pathophysiological mechanism. Inﬂammation: systemic anti-inﬂammatory use. HPA-axis: awakening time, working status and season
during saliva collection. BDNF: systemic anti-inﬂammatory use, non-opioid analgesic-antipyretic use and selective serotonin reuptake inhibitor use. Vitamin D:
season during blood collection.
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episodes showed a borderline signiﬁcant association with CRP in
women (β=− 0.067, s.e. = 0.034, P= 0.050).
DISCUSSION
The present study examined whether progression of MDD at a
clinical level (deﬁned by clinical staging) was paralleled by more
advanced pathophysiological dysregulations. We examined four
central pathophysiological mechanisms (inﬂammation, HPA-axis,
neurotrophic growth and vitamin D). We hypothesized that
besides involvement in the etiology of MDD, these mechanisms
are also associated with clinical progression of MDD, as reﬂected
by continuously increasing dysregulation across consecutive full-
threshold stages. That hypothesis was not upheld. Three
(inﬂammation, HPA-axis and vitamin D) of the four examined
pathophysiological mechanisms showed increasing trends of
dysregulation across HCs and the at-risk stages (0, 1A and 1B) of
depression, but not across the full-threshold stages (2, 3A, 3B, 3C
and 4). These results suggest that mechanisms involved in the
etiology of depression are not associated with clinical progression
of depression.
Our ﬁnding that the pathophysiological mechanisms are
involved in the etiology of depression conﬁrms previous
meta-analysis6–9,15,17 and longitudinal studies.12,38–41 Interestingly,
we did not ﬁnd any association between BDNF and MDD groups/
stages, which is in contrast with previous studies that found lower
BDNF levels in untreated currently depressed patients that
normalize in treated patients.15 However, our results are in line
with more recent studies that showed that the association between
BDNF and MDD etiology is still unclear and modest at the best;
moreover, BDNF seems rather to modulate the treatment efﬁcacy.42
We have tested the hypothesis that the examined mechanisms
could also be associated with clinical progression of MDD. Although
this intriguing research hypothesis generates mainly from data on
animal studies,5 the few observational studies on humans support-
ing it included small sample sizes,43 consisted of very selective
samples12,44,45 or only examined one aspect of depression progress-
ion, for example, recurrence.13 To our knowledge, this is the ﬁrst
study that, within a large sample, tested whether pathophysiolog-
ical mechanisms show more dysregulation in clinically more
progressed depression, as deﬁned by the tool clinical staging. Using
this approach, we found that the examined mechanisms are not
more dysregulated in clinically progressed MDD. Moreover, when
we examined whether the separate clinical measures (severity,
duration and number of episodes) that build up the staging model
were associated with more dysregulation in the pathophysiologi-
cal mechanism, we did not ﬁnd an association either. Together
these results strongly suggest that the examined mechanisms are
not more dysregulated in clinically progressed MDD. When the
examined mechanisms would have shown more dysregulation in
clinically progressed MDD, the mechanisms could have contrib-
uted to an index to separate different stages of MDD progression
( = biomarker of stage46). The clinical utility of using pathophysio-
logical markers as an objective measure to separate stages of
Table 4. Associations between severity, duration, number of episodes and pathophysiological markers with the full-threshold MDD stages
(stage 2 through 4).
Severity (IDS score) Duration (% of time with depressive symptoms in 3
years before baseline)
Number of episodes
Beta s.e. P-value Beta s.e. P-value Beta s.e. P-value
Inﬂammation




− 0.006 0.049 0.910 − 0.029 0.047 0.534 − 0.026 0.048 0.597




− 0.031 0.035 0.376 0.006 0.034 0.847 − 0.067 0.034 0.050
Interleukin-6 (pgml−1) 0.020 0.038 0.599 − 0.015 0.037 0.679 − 0.028 0.037 0.456
HPA-axis
n= 676 n= 617–617–669–636 n= 619–619–672–639 n= 600–600–653–621
AUCg (nmol l−1 h−1) − 0.086 0.040 0.034 − 0.059 0.039 0.128 − 0.014 0.040 0.717
AUCi (nmol l−1 h−1) − 0.002 0.042 0.956 0.020 0.040 0.613 − 0.008 0.041 0.836
Mean evening cortisol
(nmol l−1)
− 0.046 0.037 0.215 − 0.048 0.036 0.173 − 0.026 0.036 0.482
Cortisol suppression ratio − 0.062 0.041 0.135 0.015 0.040 0.711 0.005 0.041 0.897
Neurotrophic growth
n= 1068 n= 1050 n= 1067 n= 1033
BDNF (ngml−1) − 0.008 0.032 0.811 0.022 0.031 0.473 − 0.018 0.032 0.562
Vitamin D
n= 1074 n= 1055 n= 1073 n= 1039
25(OH)D (nmol l−1) − 0.039 0.031 0.214 −0.022 0.030 0.458 0.034 0.030 0.252
Abbreviations: AUCg/i, area under the curve with respect to the ground/increase; BDNF, brain-derived neurotrophic factor; HPA, hypothalamic–pituitary axis;
IDS, Inventory of Depressive Symptoms; MDD, major depressive disorder. Clinical characteristics of MDD to predict measures of pathophysiological
mechanisms, characteristics that together are used to create the staging model. Adjusted for age; gender (except inﬂammation analyses, as these were
stratiﬁed by gender); years of education; alcohol status; smoking status; number of chronic diseases under treatment; body mass index. Inﬂammation: systemic
anti-Inﬂammatory use. HPA-axis: awakening time, working status and season during saliva collection. BDNF: systemic anti-Inﬂammatory use, non-opioid
analgesic-antipyretic use and selective serotonin reuptake inhibitor use. Vitamin D: season during blood collection. Due to missing values in severity score,
duration and number of episodes, the included number of participants is lower for these analyses. For example, our full-threshold MDD stages included 1074
participants with a vitamin D value; of those, 1055 had a severity score. Severity score was necessary to divide between stage 2 and 3A; however, those in
stage 3B, 3C and 4 did not need a severity score to be staged.
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disease progression is evident from somatic disorders. For instance,
kidney failure knows ﬁve stadia based on the estimated glomerular
ﬁltration rate, inter alia based on serum creatinine level,47 a
relatively easy and very objective measure. Stages of disease
progression have clinical signiﬁcance for prognosis and choice of
therapeutic modality.22 For example, it has helped to make the case
for early detection and to devise speciﬁc treatments for speciﬁc
stages of kidney failure.47 It has been hypothesized that application
of staging to MDD may have similar beneﬁts.48,49 However, the here
examined mechanisms cannot be used as an index to separate
different stages of MDD progression. It could be, however, that
other pathophysiological mechanisms are more dysregulated in
clinically progressed MDD. For instance, besides the mechanisms
we studied for progression, Moylan et al.,5 suggest inter alia
neurotransmitter systems, oxidative and nitrosative stress, mito-
chondrial dysfunction and epigenetic inﬂuences. Furthermore, it
could be that the examined mechanisms are involved in disease
progression only in certain subtypes of depression, or only in
patients with certain clinical characteristics. For example, previous
research has shown that upregulation of inﬂammation is mainly
present in those with atypical depression, and hypercortisolemia in
those with melancholic depression.50 Those that experienced a
childhood trauma had instead lower cortisol levels.13,51,52 Moreover,
as recently well described by Davis et al.46 it might be that the
examined mechanism markers are not biomarkers of stage, but are
biomarkers of diagnosis/trait (inﬂammation, cortisol and vitamin D)
indicating whether in a person a depression is present or not, or
biomarkers of treatment response (BDNF) indicating whether an
individual is likely to respond to a certain treatment or not, ideally
giving the clinician the opportunity to personalize treatments to
individual needs. Finally, it is very well possible that clinical
progression of MDD is not driven by increased dysregulation of the
studied mechanisms, but rather by prolonged exposure to a chronic
level of dysregulation that then leads to damage/alterations of
cellular components, which subsequently could cause a person to
be at further risk of recurrence or chronicity of MDD.
The main strengths of our study are the large number of well-
diagnosed patients in the whole adult age range representing
different developmental stages of MDD, and the availability of a
wide range of important confounders regarding the examined
pathophysiological mechanisms. However, our study also has
some limitations. First, biological measurements were obtained via
a blood draw or saliva collection, which are peripheral measure-
ments that may not necessarily represent the ‘central/brain’
mechanism relevant for depression. However, they have
been consistently associated with MDD status in previous
studies.6–9,15,17 Furthermore, whether the measured markers are
the best indexes for the candidate mechanisms of depression
pathophysiology has not been deﬁnitely established. Second, we
used a staging model to deﬁne clinical progression of MDD in a
cross-sectional sample. To make a deﬁnite statement about
involvement of the mechanisms in clinical progression of MDD,
a longitudinal study would be necessary in which markers are
preferably measured before onset of depression, during and after
the ﬁrst and follow-up episodes. Third, we used the most applied
staging model for MDD that stages patients mainly according to
disease episode number and duration. When we separately tested
the clinical characteristics of severity, duration and number of
episodes, none of them were consistently associated with the
measured mechanism markers. It might be that aspects of disease
that were omitted in the staging model, such as complications,
functional outcome and comorbidity, are of more importance for
clinical MDD progression. Indeed some studies showed an
association between the pathophysiological dysregulations and
suicidal ideation (inﬂammation53 and HPA54) and comorbidity
(inﬂammation,55 HPA56 and vitamin D57). Finally, we like to
acknowledge that different staging models for MDD exist,58
besides the one we have chosen to use.27 The main difference is
that those models collapse stage 3A—incomplete remission of
ﬁrst episode, stage 3B—ﬁrst relapse and stage 3C—multiple
recurrent episodes into one stage three-relapsing/reoccurring
MDD. The decision to use the extensive staging model was based
on our previous ﬁnding that stage 3A in general had worse
characteristics than the sublevel 3B and 3C, and scores more
similar as stage 4 (chronic MDD).32
In conclusion, three candidate pathophysiologic mechanisms
(inﬂammation, HPA-axis and vitamin D) show increased dysregu-
lation across controls and at-risk stages of development of MDD,
suggesting involvement in the etiology of MDD. Nevertheless, the
same mechanisms did not show more dysregulation in clinical
progression of MDD toward multiple episodes and/or chronicity.
This suggests that pathophysiological mechanisms for etiology
and clinical disease progression are not necessarily overlapping.
More (longitudinal) research on pathophysiological mechanisms
that drive clinical disease progression is needed in order to be
able to use dysregulations in those mechanisms as markers of
clinical progression of depression and in such for staging.
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